Project Grant R03HL178875
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $759,983.00 to the University of North Carolina at Chapel Hill to conduct research on the role of neutrophils in lung infections and acute lung injury. The study aims to examine changes in neutrophil transcriptomes and function during Streptococcus pneumoniae pneumonia, with the goal of improving understanding of the lung's immune response and potential...
- This $775,992 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research by the University of North Carolina at Chapel Hill to investigate the role of regulatory T cells and glucocorticoids in the resolution of acute lung injury and acute respiratory distress syndrome (ARDS). The research aims to determine how glucocorticoid signaling through regulatory T cells impacts the recovery of lung structure and function following...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $161,890 to the University of Washington (UW) to support research on the role of alveolar macrophages in the host response to gram-negative bacterial pulmonary infections, such as those caused by Burkholderia pseudomallei. The research aims to elucidate the significance of alveolar macrophages as an intracellular replication niche for Burkholderia species, as well...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,659,996.00 to the University of Southern California (USC) to investigate the role of the NF-kappaB modulator PDLIM2 in alveolar macrophages and its impact on lung innate immunity, inflammation, and diseases. The research aims to elucidate how alveolar macrophages, which are critical for lung defense, can promote lung cancer and increase vulnerability to...
- The University of Washington received a $880,735 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The award will support research to examine the mechanisms through which cell lysis and leukotriene synthesis activate type-2 immunity in the lung. Key objectives include identifying alveolar macrophages as a source of leukotriene C4 and studying how its synthesis is regulated, as well as investigating...
- This Project Grant award for $744,880.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate how lactate produced by alveolar epithelial type II cells can shift alveolar macrophages towards an anti-inflammatory phenotype, which could enable therapeutic exploitation of this innate protective mechanism in acute lung injury and acute respiratory distress syndrome. The...
- This $1,831,848 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate how early-life disruptions to gut microbiota colonization can remodel the development of lung immune and epithelial cells, contributing to chronic respiratory diseases. The research aims to identify the critical window and key microbial taxa required for establishing long-term lung homeostasis. Preliminary data indicates that...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,061,189 to the Regents of the University of Michigan to conduct research on immune crosstalk in lung injury and fibrosis. The key objectives are to study epithelial cell regulation of fibrosis and its interaction with myeloid cells, uncover mechanisms for impaired innate immunity against gram-positive infections in fibrosis, test delivery of targeted therapeutics...
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $188,892 Project Grant to the University of Washington to support research on the role of CD163+ blood monocytes and lung macrophages in progressive pulmonary fibrosis. This 5-year grant, starting August 1, 2025, will fund a physician-scientist's research plan that leverages the university's expertise in immunology, bioinformatics, and lung biology to...
- This Project Grant award of $796,189.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of Illinois to define the dynamics of neutrophil subpopulations and their role in inflammatory lung injury and repair. The study aims to identify the distinct functions of the CXCR2 and CXCR4 chemokine receptors in regulating neutrophil trafficking and activation during acute lung inflammation, with the goal of developing...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $233,250 to the University of North Carolina at Chapel Hill (UNC-CH) to investigate the role of lipid metabolism in lung macrophage activity and phenotypes during acute lung injury. The project aims to understand how changes in lipid metabolism alter the function of lung macrophages during influenza A virus infection, which can lead to lung inflammation and injury. The award period is from September 1, 2025 to August 31, 2027. The research builds on UNC-CH's expertise in cardiovascular and pulmonary disease research, leveraging the institution's capabilities in advanced scientific investigations, clinical studies, and interdisciplinary research solutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $233.3k | 8/6/25 |